Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Johnson and Johnson's Covid-19 vaccine generates 'promising' immune response

Wed 13 January 2021 22:42 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Johnson&Johnson's Covid-19 vaccine generated a 'promising' immune response, results from from phase one and two clinical trials showed.

Most of the volunteers taking part in the trials showed detectable neutralising antibodies 28 days after being administered the shot.

By day 57 all volunteers, with ages ranging from 18 to those 65 or older, had detectable antibodies, regardless of whether they were given a low or high dose of the vaccine.

Among those aged 18 to 55, the level of antibodies had remained stable for at least 71 days.

The data, which was published in the New England Journal of Medicine, also showed that the vaccine was safe.

In remarks to CNBC, J&J's Chief Scientific Officer, Paul Stoffels, said the readings from the trial gave his company "confidence" that the vaccine would prove highly effective in countering the virus.

According to CNBC, results from the ongoing 45,000-person phase three trial were expected later in January.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More company news from ShareCast